Cost-effectiveness of several atypical antipsychotics in orally disintegrating tablets compared with standard oral tablets in the treatment of schizophrenia in the United States

References

• Cramer JA, Rosenheck R. Compliance with medication regimens for mental and physical disorders. Psychiatr Serv 1998;49:196-201
   PubMed Web of Science ®Google Scholar
• Ascher-Svanum H, Zhu B, Faries D, et al. A comparison of olanzapine and risperidone on the risk of psychiatric hospitalization in the naturalistic treatment of patients with schizophrenia. Ann Gen Hosp Psychiatry 2004;3:11
   PubMedGoogle Scholar
• Law MR, Soumerai SB, Ross-Degnan D, et al. A longitudinal study of medication nonadherence and hospitalization risk in schizophrenia. J Clin Psychiatry 2008;69:47-53
   PubMed Web of Science ®Google Scholar
• Valenstein M, Copeland LA, Blow FC, et al. Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission. Medical Care 2002;40:630-9
   PubMed Web of Science ®Google Scholar
• Marcus SC, Olfson M. Outpatient antipsychotic treatment and inpatient costs of schizophrenia. Schizophr Bull 2008;34:173-80
   PubMed Web of Science ®Google Scholar
• Chue P, Jones B, Taylor CC, et al. Dissolution profile, tolerability, and acceptability of the orally disintegrating olanzapine tablet in patients with schizophrenia. Can J Psychiatry 2002;47:771-4
   PubMed Web of Science ®Google Scholar
• Keith S. Advances in psychotropic formulations. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:996-1008
   PubMed Web of Science ®Google Scholar
• Wertheimer AI, Santella TM, Finestone AJ, et al. Drug delivery systems improve pharmaceutical profile and facilitate medication adherence. Adv Ther 2005;22:559-77
   PubMed Web of Science ®Google Scholar
• Bogner RH, Wilkosz MF. Fast-dissolving tablets: new dosage convenience for patients. US Pharmacist 2002;27:34-43
   Google Scholar
• Kuchekar BS, Badhan AC, Mahajan HS. Mouth dissolving tablets: a novel drug delivery system. Pharma Times 2003;35:7-9
   Google Scholar
• Kinon BJ, Hill AL, Liu H, et al. Olanzapine orally disintegrating tablets in the treatment of acutely ill non-compliant patients with schizophrenia. Int J Neuropsychopharmacol 2003;6:97-102
   PubMed Web of Science ®Google Scholar
• Czekalla J, Wagner T, Schact A, et al. Effectiveness and medication acceptance of olanzapine disintegrating tablets compared to standard olanzapine tablets in acutely treated psychiatric patients. Patient Prefer Adherence 2007;1:19-27
   PubMedGoogle Scholar
• Karagianis J, Grossman L, Lee B, et al. A 16-week, randomized, double-blind, double-dummy trial of sublingual orally disintegrating olanzapine vs standard olanzapine tablets in patients who gained weight during olanzapine. Schizophr Res 2008; 102:Suppl 2. http://www.sciencedirect.com/science/article/pii/S0920996408707175 [Accessed February 2012]
   Google Scholar
• Ciorabai EM, Oyffe I, Dilbaz N, et al. Patients preference of olanzapine orodipersible tablets compared with olanzapine classic oral tablet in a multinational randomized crossover study. Eur Psychiatry 2008;23(2 Suppl):S150-1
   Google Scholar
• San L, Casillas M, Ciudad A, et al. Olanzapine orally disintegrating tablet: a review of efficacy and compliance. CNS Neurosci Ther 2008;14:203-14
   PubMed Web of Science ®Google Scholar
• Furiak NM, Ascher-Svanum H, Klein RW, et al. Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States. Cost Eff Resour Alloc 2009;7:4
   PubMedGoogle Scholar
• Bettonvil B, Kleijnen JPC. Searching for important factors in simulation models with many factors: sequential bifurcation. Eur J Oper Res 1997;96:180-94
   Web of Science ®Google Scholar
• Zhao Z. A retrospective economic evaluation of olanzapine versus risperidone in the treatment of schizophrenia. Manag Care Interface 2002;15:75-81
   PubMedGoogle Scholar
• Rascati KL, Johnsrud MT, Crismon ML, et al. Olanzapine versus risperidone in the treatment of schizophrenia: a comparison of costs among Texas Medicaid recipients. Pharmacoeconomics 2003;21:683-97
   PubMed Web of Science ®Google Scholar
• Gilmer TP, Dolder CR, Lacro JP, et al. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry 2004;161:692-9
   PubMed Web of Science ®Google Scholar
• Gibson PJ, Damler R, Jackson EA, et al. The impact of olanzapine, risperidone, or haloperidol on the cost of schizophrenia care in a medicaid population. Value Health 2004;7:22-35
   PubMed Web of Science ®Google Scholar
• Ascher-Svanum H, Zhu B, Faries DE, et al. Adherence and persistence to typical and atypical antipsychotics in the naturalistic treatment of patients with schizophrenia. Patient Prefer Adherence 2008;2:67-77
   PubMedGoogle Scholar
• Ascher-Svanum H, Zhu B, Faries DE, et al. Medication adherence levels and differential use of mental-health services in the treatment of schizophrenia. BMC Res Notes 2009;2:6
   PubMedGoogle Scholar
• Karagianis J, Grossman L, Landry J, et al. A randomized controlled trial of the effect of sublingual orally disintegrating olanzapine versus oral olanzapine on body mass index: the PLATYPUS Study. Schizophr Res 2009;113:41-8
   PubMed Web of Science ®Google Scholar
• Ahn J, McCombs JS, Jung C, et al. Classifying patients by antipsychotic adherence patterns using latent class analysis: characteristics of nonadherent groups in the California Medicaid (Medi-Cal) program. Value Health 2008;11:48-56
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-23
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia [Erratum]. N Engl J Med 2010;363:1092-3
   Web of Science ®Google Scholar
• Zimbroff D, Warrington L, Loebel A, et al. Comparison of ziprasidone and aripiprazole in acutely ill patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, 4-week study. Int Clin Psychopharmacol 2007;22:363-70
   PubMed Web of Science ®Google Scholar
• Agency for Healthcare Research and Quality (AHRQ). HCUP Nationwide Inpatient Sample (NIS), 2004. Healthcare Cost and Utilization Project (HCUP). Agency for Healthcare Research and Quality. Rockville, MD: AHRQ, 2004. http://hcupnet.ahrq.gov/HCUPnet.jsp. [Accessed 9 December 2010]
   Google Scholar
• Olfson M, Mechanic D, Hansell S, et al. Predicting medication noncompliance after hospital discharge among patients with schizophrenia. Psychiatr Serv 2000;51:216-22
   PubMed Web of Science ®Google Scholar
• Tiihonen J, Wahlbeck K, Lonnqvist J, et al. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ 2006;333:224
   PubMed Web of Science ®Google Scholar
• Edwards NC, Locklear JC, Rupnow MF, et al. Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA. Pharmacoeconomics 2005;23(1 Suppl):75-89
   PubMedGoogle Scholar
• Siris SG. Suicide and schizophrenia. J Psychopharmacol 2001;15:127-35
   PubMed Web of Science ®Google Scholar
• Lambert BL, Cunningham FE, Miller DR, et al. Diabetes risk associated with use of olanzapine, quetiapine, and risperidone in veterans health administration patients with schizophrenia. Am J Epidemiol 2006;164:672-81
   PubMed Web of Science ®Google Scholar
• Fleischhacker WW, McQuade RD, Marcus RN, et al. A double-blind, randomized comparative study of aripiprazole and olanzapine in patients with schizophrenia. Biol Psychiatry 2009;65:510-7
   PubMed Web of Science ®Google Scholar
• Carlson CD, Cavazzoni PA, Berg PH, et al. An integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, haloperidol, risperidone, or clozapine. J Clin Psychiatry 2003;64:898-906
   PubMed Web of Science ®Google Scholar
• Lenert LA, Sturley AP, Rapaport MH, et al. Public preferences for health states with schizophrenia and a mapping function to estimate utilities from positive and negative symptom scale scores. Schizophr Res 2004;71:155-65
   PubMed Web of Science ®Google Scholar
• Conley RR, Mahmoud R. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am J Psychiatry 2001;158:765-74
   PubMed Web of Science ®Google Scholar
• Kern RS, Green MF, Cornblatt BA, et al. The neurocognitive effects of aripiprazole: an open-label comparison with olanzapine. Psychopharmacology (Berl) 2006;187:312-20
   PubMed Web of Science ®Google Scholar
• Analysource Data. AWP/NWP cost of antipsychotics. www.Analysource.com. Accessed December 9, 2010
   Google Scholar
• Tunis SL, Faries DE, Nyhuis AW, et al. Cost-effectiveness of olanzapine as first-line treatment for schizophrenia: results from a randomized, open-label, 1-year trial. Value Health 2006;9:77-89
   PubMed Web of Science ®Google Scholar
• Bureau of Labor Statistics. Consumer Price Index – Medical Services Component. United States Department of Labor, 2010. http://data.bls.gov/cgi-bin/surveymost?cu. Accessed 6 September 2011
   Google Scholar
• Vera-Llonch M, Delea TE, Richardson E, et al. Outcomes and costs of risperidone versus olanzapine in patients with chronic schizophrenia or schizoaffective disorders: a Markov model. Value Health 2004;7:569-84
   PubMed Web of Science ®Google Scholar
• Marder SR, Essock SM, Miller AL, et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004;161:1334-49
   PubMed Web of Science ®Google Scholar
• drugstore.com. 2011. http://www.drugstore.com/pharmacy/prices/drugprice.asp?ndc=00006074954&trx=1Z5006; Accessed 7 September 2011
   Google Scholar
• Leucht S, Komossa K, Rummel-Kluge C, et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry 2009;166:152-63
   PubMed Web of Science ®Google Scholar
• Ascher-Svanum H, Stensland MD, Peng X, et al. Cost-effectiveness of olanzapine vs. aripiprazole in the treatment of schizophrenia. Curr Med Res Opin 2011;27:115-22
   PubMed Web of Science ®Google Scholar